erythropoietin receptor signaling mitigates renal dysfunction-associated heart failure by mechanisms unrelated to relief of anemia外文参考.pdf

Journal of the American College of Cardiology saline (control), recombinant human erythropoietin (rhEPO) at 5,000 IU (714 pmol)/kg, or asialoEPO at 714
pmol/kg, twice/week for 4 weeks.
Results Although only rhEPO relieved the nephrectomy-induced anemia, both rhEPO and asialoEPO significantly and sim-
ilarly mitigated left ventricular dilation and dysfunction. The hearts of rhEPO- or asialoEPO-treated mice showed
less hypertrophy, reflecting decreases in cardiomyocyte hypertrophy and degenerative subcellular changes, as
well as significant attenuation of fibrosis, leukocyte infiltration, and oxidative deoxyribonucleic acid damage.
These phenotypes were accompanied by restored expression of GATA-4, sarcomeric proteins, and vascular endo-
thelial growth factor and decreased inflammatory cytokines and lipid peroxidation. Finally, myocardial activation
was observed of extracellular signal-regulated protein kinase and signal transducer and activator of transcription
pathways in the treated mice.
Conclusions EPO receptor s